Weekly Investment Analysts’ Ratings Updates for Cognyte Software (CGNT)

Several analysts have recently updated their ratings and price targets for Cognyte Software (NASDAQ: CGNT):

• 4/11/2024 – Cognyte Software had its price target raised by analysts at Wedbush from $5.00 to $8.00. They now have a “neutral” rating on the stock.
• 4/10/2024 – Cognyte Software was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 4/10/2024 – Cognyte Software had its price target raised by analysts at Evercore ISI from $5.00 to $7.50. They now have an “in-line” rating on the stock.
• 4/9/2024 – Cognyte Software had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 3/7/2024 – Cognyte Software was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 2/28/2024 – Cognyte Software was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.

Cognyte Software Price Performance

Shares of Cognyte Software stock traded down $0.12 on Friday, hitting $6.42. The company had a trading volume of 418,703 shares, compared to its average volume of 449,361. The company has a market cap of $455.97 million, a PE ratio of -27.91 and a beta of 1.68. Cognyte Software Ltd. has a 52 week low of $4.00 and a 52 week high of $8.53. The business has a 50-day simple moving average of $7.54 and a 200-day simple moving average of $6.18.

Institutional Trading of Cognyte Software

A number of large investors have recently added to or reduced their stakes in CGNT. Legal & General Group Plc lifted its position in shares of Cognyte Software by 1.1% in the 2nd quarter. Legal & General Group Plc now owns 4,231,696 shares of the medical device company’s stock valued at $17,985,000 after acquiring an additional 48,011 shares in the last quarter. Neuberger Berman Group LLC lifted its position in shares of Cognyte Software by 5.7% in the 3rd quarter. Neuberger Berman Group LLC now owns 4,047,169 shares of the medical device company’s stock valued at $16,402,000 after acquiring an additional 218,294 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Cognyte Software by 42.9% in the 1st quarter. Ameriprise Financial Inc. now owns 2,285,073 shares of the medical device company’s stock valued at $7,746,000 after acquiring an additional 685,890 shares in the last quarter. BlackRock Inc. lifted its position in shares of Cognyte Software by 15.5% in the 3rd quarter. BlackRock Inc. now owns 2,065,372 shares of the medical device company’s stock valued at $8,342,000 after acquiring an additional 276,781 shares in the last quarter. Finally, Edenbrook Capital LLC lifted its position in shares of Cognyte Software by 144.0% in the 1st quarter. Edenbrook Capital LLC now owns 1,967,866 shares of the medical device company’s stock valued at $22,256,000 after acquiring an additional 1,161,200 shares in the last quarter. 72.92% of the stock is currently owned by institutional investors.

Cognyte Software Ltd. provides an investigative analytics software to governments and enterprises worldwide. Its Actionable Intelligence for a Safer World, an open software designed to help governments and enterprises accelerate and enhance the effectiveness of investigations. The company also offers network intelligence analytics, open source and threat intelligence analytics, and operational intelligence analytics solutions.